Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Journal Article
| Authors: | Lacouture, M. E.; Anadkat, M. J.; Bensadoun, R. J.; Bryce, J.; Chan, A.; Epstein, J. B.; Eaby-Sandy, B.; Murphy, B. A. |
| Article Title: | Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities |
| Abstract: | Background: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. Methods: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Results: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion: Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies. © 2011 Springer-Verlag. |
| Keywords: | treatment response; clinical feature; disease course; review; erlotinib; placebo; monotherapy; side effect; skin toxicity; treatment duration; skin manifestation; cancer radiotherapy; radiation dose; disease association; sunscreen; unindexed drug; low drug dose; quality of life; mucosa inflammation; sedation; practice guideline; cetuximab; risk factor; sex ratio; monoclonal antibody; protein tyrosine kinase inhibitor; drug hypersensitivity; pruritus; rash; disease severity; head and neck cancer; systematic review; eflornithine; prophylaxis; acne; pentoxifylline; xerostomia; protein secretion; hair disease; vitamin supplementation; methylprednisolone; dermatitis; age distribution; hydrocortisone; isotretinoin; corticosteroid; zinc; doxycycline; risk reduction; drug treatment failure; minocycline; alopecia; esthetic surgery; mucositis; radiation dermatitis; urticaria; recommendations; epidermal growth factor receptor kinase inhibitor; paronychia; skin fissure; xerosis; gabapentin; diphenhydramine; cryotherapy; hair loss; low level laser therapy; hypertrichosis; randomized controlled trial (topic); egfr inhibitors; pregabalin; clindamycin; fluocinonide; papulopustular rash; trichomegaly; hirsutism; hair growth; alclometasone; beclometasone; betamethasone; hydroxyzine; loratadine; menadione; minoxidil; mometasone furoate; atopic dermatitis; oral mucosal disease; papulopustural rash |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 19 |
| Issue: | 8 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2011-08-01 |
| Start Page: | 1079 |
| End Page: | 1095 |
| Language: | English |
| DOI: | 10.1007/s00520-011-1197-6 |
| PROVIDER: | scopus |
| PMCID: | PMC3128700 |
| PUBMED: | 21630130 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 October 2011" - "CODEN: SCCAE" - "Source: Scopus" |
